RA CAPITAL MANAGEMENT, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001346824

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q1 2026 · 85 positions · Total reported value $9.44B · Top-10 concentration 61.3% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.4% · 15 new · 12 cut · 11 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.6% · vs SPY -15.8% · Prev Value $11.51B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.6% · vs SPY -3.7% · Latest Value $9.72B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q1 2026 13F filing, RA CAPITAL MANAGEMENT, L.P. disclosed 85 equity positions with a combined reported value of $9.44B. The filing implies a focused portfolio: its ten largest positions account for 61.3% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2026 were ASND ($2.35B), PCVX ($666.79M), RYTM ($579.81M). By sector, the heaviest allocations are Health Care 96.7%, Technology 0.3%. Versus the prior quarter, allocation shifted toward Health Care (+13.7pp) and away from Other (-14.0pp).

Versus the prior quarter, RA CAPITAL MANAGEMENT, L.P. opened 15 new positions, trimmed 12 and fully exited 11, a turnover rate of 38.4% of positions. The portfolio's overlap with the prior quarter was 64% of names.

The largest new positions opened in Q1 2026 were SGP ($207.83M), ZLAB ($107.35M), SRPT ($84.92M).

Of the 11 positions fully exited versus the prior quarter, the largest were CDTX ($743.41M), RNAM ($623.28M), ACLX ($82.62M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2026)

  • SGP SPYGLASS PHARMA INC · $207.83M
  • ZLAB ZAI LAB LTD · $107.35M
  • SRPT SAREPTA THERAPEUTICS INC · $84.92M
  • DMRA DAMORA THERAPEUTICS INC · $62.14M
  • XNCR XENCOR INC · $59.06M
  • IPSC CENTURY THERAPEUTICS INC · $40.13M
  • MIRM MIRUM PHARMACEUTICALS INC · $29.43M
  • BIOA BIOAGE LABS INC · $28.87M

Fully Exited (vs previous quarter)

  • CDTX CIDARA THERAPEUTICS INC COM NEW · prev qtr: $743.41M
  • RNAM AVIDITY BIOSCIENCES INC · prev qtr: $623.28M
  • ACLX ARCELLX INC · prev qtr: $82.62M
  • BLTE BELITE BIO INC · prev qtr: $69.18M
  • IVVD INVIVYD INC · prev qtr: $42.28M
  • MDLN MEDLINE INC · prev qtr: $14.07M
  • PGNY PROGYNY INC · prev qtr: $2.48M
  • QGEN QIAGEN NV · prev qtr: $2.08M

Insider Transactions (Form 4)

Latest RA CAPITAL MANAGEMENT, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 164,891 $16.00 SEC filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 2,335,109 $16.00 SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 1,331,080 — SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 3,144,858 — SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 263,911 $14.92 SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 189,909 $14.23 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 107,170 $3.36 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 451,998 $3.36 SEC filing

All insider transactions →

Fund Profile

RA Capital Management is a Boston-based investment firm founded by Peter Kiernan, specializing in healthcare-focused investments with a long-term, value-oriented approach.

Investment Approach

Focuses on healthcare sector investments

Long-term, value-oriented strategy

Deep fundamental research and analysis

Asset Classes & Strategy

Primarily invests in public equities

Also manages private investments in healthcare companies

Concentrated portfolio approach with significant positions in healthcare companies

Key Personnel

Peter Kiernan: Founder and portfolio manager

Team of experienced investment professionals with healthcare expertise

Notable Facts

Founded in 2002

Manages approximately $16.4 billion in assets

Files SEC Form 13F for US equity positions

This profile is based on publicly available information and should not be considered as official disclosure from the firm.

Sector Allocation

Health Care 96.7%
Technology 0.3%
Financials 0.1%
Materials 0.1%
Other 2.8%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 10.28M $2.35B 24.92%
24.92%
Hold
2 11.47M $666.79M 7.07%
7.07%
Add
3 6.67M $579.81M 6.14%
6.14%
Hold
4 12.20M $467.21M 4.95%
4.95%
Hold
5 9.91M $397.09M 4.21%
4.21%
Hold
6 10.43M $328.50M 3.48%
3.48%
Hold
7 9.55M $305.70M 3.24%
3.24%
Hold
8 2.53M $259.62M 2.75%
2.75%
Add
9 2.61M $219.18M 2.32%
2.32%
Add
10 7.69M $208.40M 2.21%
2.21%
Add
11 8.02M $207.83M 2.20%
2.20%
New
12 26.98M $195.57M 2.07%
Form 4 · 1 →
2.07%
Add
13 7.00M $168.11M 1.78%
1.78%
Hold
14 2.45M $156.67M 1.66%
1.66%
Add
15 11.19M $155.54M 1.65%
1.65%
Hold
16 15.83M $150.67M 1.60%
1.60%
Hold
17 7.26M $144.32M 1.53%
1.53%
Add
18 373.79K $120.43M 1.28%
1.28%
Hold
19 7.68M $107.93M 1.14%
1.14%
Hold
20 5.71M $107.35M 1.14%
1.14%
New
21 23.56M $105.29M 1.12%
1.12%
Hold
22 5.40M $96.43M 1.02%
Form 4 · 1 →
1.02%
Hold
23 63.77M $95.02M 1.01%
1.01%
Hold
24 10.86M $87.21M 0.92%
0.92%
Hold
25 3.90M $84.92M 0.90%
0.90%
New
26 1.62M $81.79M 0.87%
0.87%
Hold
27 3.49M $80.34M 0.85%
0.85%
Add
28 11.30M $77.41M 0.82%
Form 4 · 4 →
0.82%
Hold
29 9.34M $67.25M 0.71%
0.71%
Add
30 9.85M $63.46M 0.67%
0.67%
Hold
31 2.40M $62.14M 0.66%
0.66%
New
32 4.90M $59.06M 0.63%
0.63%
New
33 2.21M $54.46M 0.58%
0.58%
Hold
34 3.67M $51.58M 0.55%
0.55%
Hold
35 20.99M $49.54M 0.53%
0.53%
Add
36 5.05M $47.01M 0.50%
0.50%
Reduce
37 6.05M $46.43M 0.49%
0.49%
Hold
38 1.51M $45.84M 0.49%
0.49%
Hold
39 17.75M $40.13M 0.42%
0.42%
New
40 2.60M $38.77M 0.41%
0.41%
Hold
41 4.18M $38.24M 0.41%
Form 4 · 3 →
0.41%
Hold
42 667.21K $36.56M 0.39%
0.39%
Hold
43 20.06M $35.51M 0.38%
0.38%
Hold
44 2.97M $31.63M 0.34%
0.34%
Add
45 318.55K $29.43M 0.31%
0.31%
New
46 1.65M $28.87M 0.31%
0.31%
New
47 5.00M $28.70M 0.30%
0.30%
Hold
48 1.02M $28.32M 0.30%
0.30%
Hold
49 9.18M $28.00M 0.30%
0.30%
Hold
50 1.50M $26.89M 0.28%
0.28%
New

FAQ

What did RA CAPITAL MANAGEMENT, L.P. buy in 2026-Q1?

In its 2026-Q1 13F filing, RA CAPITAL MANAGEMENT, L.P. reported 85 equity positions worth $9.44B in aggregate; its largest disclosed positions were ASND ($2.35B), PCVX ($666.79M), RYTM ($579.81M).

How large is RA CAPITAL MANAGEMENT, L.P.'s portfolio?

RA CAPITAL MANAGEMENT, L.P. reported $9.44B of long equity holdings across 85 positions as of 2026-Q1. Top-10 holdings account for 61.3% of reported value.

What is RA CAPITAL MANAGEMENT, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/ra-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →